1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Regulation

EMA Firms Up February 2025 Date For Shortages Monitoring Platform

Plans To Integrate ESMP With Other Data Sources

 
• By Dean Rudge

During the recent Medicines for Europe 2022 annual conference, held in Sitges, Barcelona, the EMA’s head of supply and availability of medicines and devices, Monica Dias, provided delegates with a detailed update on plans to implement the agency’s major shortages monitoring platform by early 2025.

EMA Building
The EMA is ramping up efforts to address shortages • Source: Alamy

The European Medicines Agency has reiterated plans to implement its European Shortages Monitoring Platform to facilitate data collection and reporting by companies and member states on shortages, supply of and demand for critical medicines, providing a targeted implementation date of 2 February 2025.

Addressing delegates to off-patent industry association Medicines for Europe’s 2022 annual conference, held in Sitges, Barcelona, last week, the EMA’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Generic Drugs And AI: Maximum Daily Dose Tool Could Help US FDA Be ‘At The Forefront’

 
• By Michael McCaughan

The FDA is testing a new artificial intelligence tool to help generic drug developers automate maximum daily dose calculations.

Repurposed Generics For Rare Diseases: Janet Woodcock Proposes Shortcut

A Duke-Margolis working group is developing ideas to enable non-profit firms to seek US FDA approval for new indications for off-patent medicines. The former acting commissioner thinks citizen petitions might be the fastest route.

Sandoz Streamlines More Trials As First-Half Biosimilars Sales Hit $1.5bn

 
• By Dave Wallace

Sandoz has revealed plans to streamline more biosimilar trials amid evolving regulatory moves towards minimizing the need for comparative efficacy studies. The disclosure was just one of many pipeline and portfolio updates provided as the firm delivered positive first-half results.

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

 
• By Vibha Ravi

Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline.

More from Policy & Regulation

‘Concrete Solutions, Not Big Words’ – Samsung Bioepis Suggests European Improvements For Biosimilars

 
• By Dave Wallace

While biosimilars have seen success in Europe, there are still plenty of areas in which policy improvements could solve problems for the market, according to a new Samsung Bioepis white paper. Adam Levysohn, the firm’s local head of commercial strategy, talks about the proposals.

Latest EMA Biosimilar Nods Come For Henlius, Alteogen And Biocon

 
• By Dave Wallace

Denosumab, aflibercept and ustekinumab biosimilars received positive opinions from the EMA’s CHMP at its meeting in July, along with an Opsumit generic from Accord.

‘Europe Has To Make Up Its Mind’ – Medicines For Europe’s Sieger On The Path Ahead

 
• By Dave Wallace

At an eventful time for the European generics and biosimilars industry, Medicines for Europe interim president and Polpharma CEO Markus Sieger talks about what the European healthcare sector needs and what the off-patent sector can deliver.